abstract: In previously untreated @entity1 with locally advanced or metastatic @entity1149 ( @entity1149 ) the combination of @entity1205 and @entity136 is active and well tolerated. In the phase II setting using a 3-week schedule, response rates (RR) ranged from 25 to 50%, and median survival from 11 to 13 months. Preliminary data with weekly and bi-weekly schedules indicate maintained efficacy while reducing the risk of @entity1398 . A randomized phase III trial has shown that the combination of @entity1205 and @entity136 is as active as @entity1205 plus @entity900 , achieving a 1-year survival rate of 39%, with significantly less @entity1398 and gastro-intestinal @entity137 . The combination of @entity1205 with @entity1206 is equally active and the associated @entity137 are manageable. In phase II studies the average response rate is 40%, and in one study using a 2-week schedule the 1-year survival rate was 60%. With this combination @entity1398 is the commonest adverse event while clinically significant @entity16 is infrequent. In a randomized phase II trial, @entity1205 plus @entity900 was compared to @entity1205 plus @entity2600 . The non- @entity902 doublet achieved comparable levels of activity, though with a different @entity137 profile (more @entity294 but less @entity390 and @entity391 ). The combination of @entity1205 with @entity2600 and @entity3003 has achieved 1-year survival of 55%. All three @entity1205 combinations ( @entity136 , @entity1206 , and @entity2600 ) could provide a valuable alternative to @entity902 -based chemotherapy and should be further evaluated in phase III setting.

title: Challenging the XXXX combinations in the chemotherapy of @entity1149 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity902 :: (MESH:D010984,Chemical) :: ['platinum']


abstract: The kidney plays an important role in the long-term regulation of blood pressure and extracellular fluid volume through the regulation of @entity1372 and water excretion. Increases in renal perfusion pressure (RPP) cause a potent natriuretic stimulus, referred to as 'pressure natriuresis', which is an important mechanism in the regulation of extracellular fluid volume and blood pressure. In normotensive animals, increases in RPP are transmitted to the renal interstitium and result in increases in @entity8 ( @entity8 ), as well as in @entity1372 and water excretion. However, pressure natriuresis is significantly attenuated in @entity101 and pregnant normotensive @entity35 . Furthermore, this response is associated with an attenuated increase in @entity8 with increases in RPP, suggesting that the renal interstitial compliance is greater in @entity101 and during pregnancy than in normotensive non-pregnant states. In the absence of other mechanisms, this attenuated pressure natriuretic response can lead to volume retention. However, volume expansion also increases @entity8 and @entity1372 excretion. It is proposed that a compensatory increase in the natriuretic sensitivity to increases in @entity8 counterbalances the volume retention that results from the attenuated pressure natriuresis in @entity101 @entity35 , and thus may play an important role in maintaining normal plasma volume in these animals. Likewise, it is also proposed that the attenuated relationship between blood pressure, @entity8 and @entity1372 excretion that is observed during normal pregnancy is due to an increase in the compliance of the renal interstitium and leads to a reduction in @entity1372 excretion and the gradual gestational volume expansion. During pregnancy, @entity8 does not increase immediately due to the large renal interstitial compliance and therefore the increased sensitivity of the natriuretic response to increases in @entity8 does not occur, and gradual volume expansion continues during normal pregnancy. However, the increased sensitivity of the natriuretic response to increases in @entity8 takes effect only after the necessary volume is retained for a normal pregnancy. Below this requisite volume expansion, the increase in @entity8 is not sufficient to activate the exaggerated natriuretic sensitivity to increases in @entity8 . Failure of these adaptive mechanisms during pregnancy can lead to disturbances in the regulation of plasma volume which, in turn, can affect amniotic fluid volume and fetal growth and may result in @entity3465 and intrauterine growth restriction, as well as @entity1468 .

title: Renal interstitial hydrostatic pressure and @entity1372 excretion in XXXX and pregnancy.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal interstitial hydrostatic pressure', 'RIHP']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['premature labour']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['pre-eclampsia']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: Background: The present study aimed to exam the inhibitory effect of @entity205 ( @entity870 ) on periodontal destruction and to further explore the correlations of @entity870 -induced attenuation of periodontal @entity604 with the expressions of gelatinases (i.e. @entity11017 ( @entity11017 ) and @entity6929 ( @entity6929 )) and their inducer, @entity42676 ( @entity42676 ). Methods: Forty SD @entity35 were randomly divided into four groups: control, @entity870 , ligature (Lig), and ligature-plus- @entity870 (Lig+ @entity870 ) groups. @entity870 group received 10 mg/Kg/day of @entity870 for 8 days. Lig group received silk ligature on selected molars. Lig+ @entity870 group received silk ligature and @entity870 treatment. The inhibitory effects of @entity870 on the ligature-induced periodontal destruction was examined with micro-CT and histometric analysis to analyze the amount of @entity6730 , crestal @entity604 , connective tissue attachment, and the surface area with inflammatory cell infiltration. The effects of @entity870 on ligature-induced expressions of gelatinases and @entity42676 in gingival tissues were examined with Western blotting and zymography, respectively. Results: By micro-CT and histology, Lig+ @entity870 group had significantly more periodontal destruction than control and @entity870 groups, but less periodontal destruction than Lig group. Consistent results were found for the expressions of gelatinases and @entity42676 among the groups demonstrating that Lig+ @entity870 group had significantly less gingival protein expression of gelatinases and @entity42676 than Lig group. Conclusion: @entity870 inhibited the expressions of gelatinase MMPs and @entity42676 , and partially prevented the periodontal destruction in ligature-induced experimental @entity2521 . The @entity870 -induced attenuation of periodontal @entity604 was strongly correlated positively with the expressions of @entity11017 , @entity6929 , and @entity42676 in gingiva.

title: Gelatinases and @entity42676 ( @entity42676 ) are Associated With XXXX Induced Attenuation of Periodontal Degradation in @entity35 .

entities_list: @entity6730 :: ('MESH:D017622', 'Disease') :: ['attachment loss']

entities_list: @entity42676 :: ('25246(Tax:10116)', 'Gene') :: ['EMMPRIN', 'extracellular matrix metalloproteinase inducer']

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['Cyclosporin-A']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

answer: @entity205 :: (MESH:D016572,Chemical) :: ['Cyclosporine-A']


abstract: BACKGROUND: The lung is the most common site of extrahepatic metastasis from @entity157 ( @entity157 ). The aim of this study was to evaluate the significance and long-term outcomes of pulmonary metastasectomy for @entity157 , especially in @entity1 with multiple nodules or repeated @entity358 . METHODS: We retrospectively analyzed 19 @entity1 who underwent pulmonary metastasectomy for @entity157 at our institution from 1993 to 2013. RESULTS: No in-hospital mortality occurred. The 19 @entity1 included 14 @entity1 . The median age was 61 (range 20-76) years. Eight @entity1 (42  %) had single pulmonary metastatic lesions, whereas 4 (21  %) had >10 lesions. Median follow-up after pulmonary metastasectomy was 23.1 (6.3-230) months. Twelve @entity1 died, and the cause of death was @entity157 progression in nine. The 1-, 3-, 5-, and 10-year overall survival rates after pulmonary metastasectomy were 89, 48, 48, and 21  %, respectively. Seven @entity1 developed @entity358 after initial pulmonary metastasectomy. Five of the seven underwent repeat metastasectomy, with a median survival time of 65  months, and 2- and 3-year survival rates of 100 and 67  %, respectively. The 2- and 3-year survival rates in the four @entity1 with >10 pulmonary nodules were 75 and 50  %, respectively. CONCLUSIONS: Surgical resection is a safe and effective treatment in selected @entity1 with pulmonary metastasis from @entity157 , even in those with multiple nodules. Repeated locoregional therapy for lung recurrence might help to improve survival in these @entity1 .

title: Clinical Significance of Multiple Pulmonary Metastasectomy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary recurrence']

answer: @entity157 :: (MESH:D006528,Disease) :: ['Hepatocellular Carcinoma']


abstract: OBJECTIVE: To evaluate practice patterns of the management of @entity5 of @entity1062 in Canada and a selected group in the United States. MATERIALS AND METHODS: Survey among radiation oncologists treating @entity5 in Canada and the RTOG GU committee members in the United States between January and March 2001. RESULTS: Response rate was 78% (73/93) in Canada and 67% (24/36) in the United States. Eighty-four percent described their clinical practice as a university affiliated teaching center, and 16% as community-based or private practice. Sixty-two percent, 31% and 7% would manage 1-5, 6-10 and > oe = 11 cases per year respectively. Almost all would perform chest x-ray (99%) and CT scan of abdomen and pelvis (100%) as staging investigation following radical inguinal orchiectomy. Forty percent also arranged CT scan of chest, while only 18% routinely obtained lymphangiogram. Seventy-eight percent offered surveillance as a management option and estimated that 20% (median) of @entity1 would choose surveillance in their practice. Among four management options: (1. surveillance, 2. radiotherapy (RT) to the para-aortic region, 3. RT to the @entity2333 (' @entity235 -leg'), 4. single-agent chemotherapy), the order of first preference was option 1 (44%), 2 (42%), and 3 (14%) for @entity1 who wish to preserve fertility. When fertility was not a major concern, it was option 2 (43%), 3 (39%), and 1 (17%). The commonest dose-fractionation schedule was 25 Gy/20 fractions (68%). Others included 25 Gy/15 f (15%), and 25.5 Gy/17 f (4%). Forty-five percent chose the para-aortic region, while 53% used the ' @entity235 -leg' as RT volume. Twenty-nine percent reduced RT volume from the ' @entity235 -leg' to the para-aortic region as the result of MRC Phase III study published in 1999. CONCLUSION: There are significant variations in the practice pattern of the management of @entity5 of @entity1062 among radiation oncologists in Canada and a selected group in the United States.

title: Survey of radiation oncologists: practice patterns of the management of XXXX of @entity1062 in Canada and a selected group in the United States.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stage I seminoma', 'genitourinary (GU) tumors']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['para-aortic and ipsilateral pelvis']

answer: @entity5 :: (MESH:D009369,Disease) :: ['stage I seminoma']


abstract: We describe two brothers with @entity66620 who are 5 and 17 years old. They were born to healthy consanguineous parents of Pakistani descent. They had severe @entity1274 and neuroimaging showed @entity6789 agenesis and other structural @entity75 . The @entity66620 is an @entity74 , first described by Chudley et al. [1997: Am J Med Genet 68:350-356]. The original description of the syndrome includes @entity1276 due to obstruction of the foramen of Monro and early-onset severe to profound @entity1274 . We review the findings in the two @entity1 we describe, four @entity1 reported in the literature and two @entity1 reported by Hendriks et al. [1999: Am J Med Genet 86:183-186] with @entity1274 , @entity6789 agenesis, and interhemispheric cysts, who may well have @entity66620 . All @entity1 had @entity1274 . The neuroimagings of all eight @entity1 showed @entity43773 , which is most likely caused by @entity6789 agenesis. Three @entity1 had other structural @entity75 : @entity6795 and gray matter @entity3664 . We suggest a revision of the clinical description since the most likely basic @entity245 is @entity6789 agenesis and not foramen of Monro obstruction.

title: Brothers with XXXX : @entity1274 , @entity6789 , and other structural @entity75 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity43773 :: ('MESH:C535973', 'Disease') :: ['colpocephaly']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain abnormalities']

entities_list: @entity3664 :: ('MESH:C548481', 'Disease') :: ['heterotopia']

entities_list: @entity66620 :: ('MESH:C535459', 'Disease') :: ['Chudley-McCullough syndrome']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['developmental defect']

entities_list: @entity6795 :: ('MESH:D054220', 'Disease') :: ['cortical dysplasia']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural deafness']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['autosomal recessive disorder']

entities_list: @entity6789 :: ('MESH:D061085', 'Disease') :: ['corpus callosum']

answer: @entity66620 :: (MESH:C535459,Disease) :: ['Chudley-McCullough syndrome']


abstract: OBJECTIVE: Online tools for managing chronic health conditions are becoming increasingly popular. Perceived benefits include ease of use, low costs, and availability but are contingent on @entity1 engagement, Internet access, and digital literacy. This article describes data collected during the recruitment phase of a study evaluating an online self-management platform for @entity302 in a U.S. Veteran population. METHODS: We used administrative data to identify and contact Veterans with a likely diagnosis of @entity302 in the @entity283 ( @entity283 ). Veterans who did not respond directly to a mailed invitation were recruited by phone to determine study interest and evaluate digital access. RESULTS: Of the 2,143 Veterans mailed study invitations, phone calls were made to 1,789 who did not specifically decline participation. Among those reached by phone (n = 1,053): 295 (28%) expressed interest in the study and an online tool, 333 (19%) reported a lack of computer and/or Internet access and 425 (40%) were not interested for other reasons. CONCLUSIONS: This study suggests an interest in online tools for managing health despite the fact that some Veterans lack computer and/or Internet access. As investment in digital health solutions grows, the @entity283 should prioritize the widespread provision of digital access to more Veterans.

title: Interest in a Digital Health Tool in Veterans With XXXX : Results of a Phone Survey.

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity283 :: ('OMIM:603663', 'Disease') :: ['VHA', 'Veterans Health Administration']

answer: @entity302 :: (MESH:D004827,Disease) :: ['Epilepsy']


abstract: OBJECTIVES: The late component of the event-related potential (ERP), @entity3493 is a marker for cognitive brain functions. The objective of this study was to examine @entity3493 parameters in @entity303 and in @entity73 ( @entity73 ), to examine whether there is a correlation between the changes in @entity3493 parameters and the type and severity of @entity303 , and to determine @entity3493 abnormalities in @entity73 in relation to the presence/absence of CT/MRI abnormalities. METHOD: Auditory event-related potentials, @entity3493 were recorded in 28 @entity73 @entity1 (14 of them with normal CT/MRI findings and 10 subjects with mild @entity67 ). In another group of @entity1 , 31 demented @entity1 were examined, of whom 17 @entity1 were diagnosed with @entity195 ( @entity195 ), and 14 @entity1 with @entity1294 ( @entity1294 ). Forty healthy volunteers served as the control group. RESULTS: Mean @entity3493 latency was significantly increased for both demented @entity1 -groups. We found that prolongation of @entity3493 latency was correlated with the severity of @entity303 . Mean @entity3493 amplitude was significantly decreased in both groups of demented @entity1 . In @entity73 , the mean latency of @entity3493 was significantly longer among @entity1 with mild @entity194 compared to control volunteers and no significant changes were found for @entity73 @entity1 with normal CT/MRI findings. Mean @entity3493 amplitude was decreased only in demented @entity1 . CONCLUSIONS: The prolongation of @entity3493 latency was significant among @entity1 with both vascular and @entity195 , and also among @entity73 @entity1 with mild @entity194 . The severity of @entity303 is positively correlated with @entity3493 latency; however, this prolongation is independent of the type of @entity303 . The structural brain changes in @entity73 are related to @entity3493 latency prolongation and thus may indicate an increased risk for developing @entity303 in @entity73 @entity1 .

title: [ XXXX in @entity73 and in @entity303 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['MCI', 'mild cognitive impairment']

entities_list: @entity1294 :: ('MESH:D015140', 'Disease') :: ['VD', 'vascular dementia']

entities_list: @entity194 :: ('MESH:D001284', 'Disease') :: ['cerebral atrophy']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's dementia"]

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular enlargement']

answer: @entity3493 :: (2033,Gene) :: ['P300']


abstract: @entity43 is the leading cause of death from gynecologic @entity5 in @entity1 in the United States. Although response rates to primary @entity902 -based therapy are high, relapse is common. The overall survival of @entity1 with advanced-stage disease has not changed dramatically over the last 20 years, even with the advent of effective combination chemotherapy. @entity1311 ( @entity1311 ) is a new chemotherapeutic agent that shows promise for the treatment of @entity1 with @entity1442 as well as those with recurrent @entity900 -refractory disease. Overall response rates have been encouraging, although there are few pathological complete remissions. In contrast to other treatments, many @entity1 achieve prolonged stable disease over multiple cycles of therapy. However, the optimal use of @entity1311 has not yet been determined. Current studies aim to evaluate dose intensity, administration schedule, multidrug regimens, sequence of drug administration, and combinations with radiation therapy. Future studies may address adjuvant therapy of early-stage disease. Results of these trials will clarify the role of @entity1311 in the primary treatment of @entity43 .

title: Future directions for @entity1311 (TAXOL) in the treatment of XXXX .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'Ovarian cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel', 'TAXOL']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: There are well known that Wnt signaling was some roles of cell differentiation at the development tissues, especially the oral and maxillofacial regions of some developmental stages. Therefore, to determine Wnt signaling in the @entity5123 tissues, we examined. The expression of @entity18142 and @entity3546 as well as the distribution of various cytoskeletal proteins @entity5822 and @entity7435 was examined in 30 cases of @entity5123 by immunohistochemistry. @entity18142 was detected in almost all @entity5 cells. The peripheral columnar cells in @entity1544 and small cuboidal cells in duct-like structures were strongly positive to @entity18142 . Although @entity3546 was clearly localized on the cell membrane of @entity5 cells, nuclear translocation was observed in small cuboidal cells and in some basaloid cells. The immunofluorescent staining pattern of @entity18142 and @entity5822 as well as @entity18142 and @entity7435 was consistent with IHC results. Thus, in @entity5123 , Wnt is involved in @entity5 cell differentiation of peripheral columnar cells forming solid nests and small peripheral columnar cells forming duct-like structures. Moreover, among the three currently known Wnt pathways, @entity3546 is the suggested pathway working during cell differentiation. Furthermore, peripheral columnar cells in solid @entity5 nests and in @entity1544 are governed by another Wnt pathway other than @entity3546 . Therefore, Wnt signaling through @entity3546 pathway may be involved in the 'mixed' differentiation characteristic of @entity5123 although another pathway may also be possibly working in other parts of the @entity5 tissue.

title: Wnt signaling as a possible promoting factor of cell differentiation in XXXX .

entities_list: @entity1544 :: ('MESH:D018307', 'Disease') :: ['squamous metaplasia']

entities_list: @entity5123 :: ('MESH:D008949', 'Disease') :: ['pleomorphic adenoma']

answer: @entity5123 :: (MESH:D008949,Disease) :: ['pleomorphic adenomas']


abstract: There is growing interest in the potential health benefits of diets that involve regular periods of fasting. While animal studies have provided compelling evidence that feeding patterns such as alternate-day fasting can increase longevity and reduce incidence of many @entity102 , the evidence from @entity1 studies is much more limited and equivocal. Additionally, although several candidate processes have been proposed to contribute to the health benefits observed in animals, the precise molecular mechanisms responsible remain to be elucidated. The study described here examined the effects of an extended fast on gene transcript profiles in peripheral blood mononuclear cells from ten apparently healthy subjects, comparing transcript profiles after an overnight fast, sampled on four occasions at weekly intervals, with those observed on a single occasion after a further 24  h of fasting. Analysis of the overnight fasted data revealed marked inter-individual differences, some of which were associated with parameters such as gender and subject body mass. For example, a striking positive association between body mass index and the expression of genes regulated by type 1 interferon was observed. Relatively subtle changes were observed following the extended fast. Nonetheless, the pattern of changes was consistent with stimulation of @entity844 oxidation, alterations in cell cycling and apoptosis and decreased expression of key pro-inflammatory genes. Stimulation of @entity844 oxidation is an expected response, most likely in all tissues, to fasting. The other processes highlighted provide indications of potential mechanisms that could contribute to the putative beneficial effects of intermittent fasting in @entity1 .

title: Transcriptome analysis of peripheral blood mononuclear cells in XXXX subjects following a 36  h fast provides evidence of effects on genes regulating inflammation, apoptosis and energy metabolism.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: Reducing @entity1 cost-sharing and engaging @entity1 in disease management activities have been shown to increase uptake of evidence-based care. OBJECTIVE: To evaluate the effect of employer purchase of a disease-specific plan with reduced cost-sharing and disease management (the @entity6 Plan/DHP) on medication adherence among eligible employees and dependents. DESIGN: Employer-level "intent to treat" cohort study, including data from eligible employees and their dependents with @entity6 , regardless of whether they were enrolled in the DHP. SETTING: Employers that contracted with a large national health plan administrator in 2009, 2010, and/or 2011. @entity1 : Ten employers that purchased the DHP and 191 employers that did not (controls). Inverse probability weighting (IPW) estimation was used to adjust for inter-group differences. INTERVENTION: The DHP includes free or low-cost medications and physician visits. Enrollment strategies and specific benefit designs are determined by the employer and vary in practice. DHP @entity1 are notified up front that they must engage in their own health care (e.g., receiving @entity6 -related screening) in order to remain enrolled. MAIN OUTCOME MEASURE: Mean employee adherence to @entity2449 , statins, and @entity1289 /ARBs at the employer level at one year post-DHP implementation, as measured by the proportion of days covered (PDC). RESULTS: Baseline adherence to the three medications was similar across DHP and control employers, ranging from 64 to 69  %. In the first year after DHP implementation, predicted employer-level adherence for @entity2449 (+4.9 percentage points, p   =   0.017), @entity6817 (+4.8, p   =   0.019), and @entity1289 /ARBs (+4.4, p   =   0.02) was higher with DHP purchase. LIMITATIONS: Non-randomized, observational study. CONCLUSIONS: The @entity6 Plan, an innovative health plan that combines reduced cost-sharing and disease management with an up-front requirement of enrollee participation in his or her own health care, is associated with a modest improvement in medication adherence at 12  months.

title: Adherence to @entity2449 , @entity6817 , and @entity1289 /ARBs Within the XXXX Plan (DHP).

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient', 'PARTICIPANTS']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes Health', 'diabetes']

entities_list: @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes Health']


abstract: BACKGROUND: Sepsis is the systemic inflammatory response to an @entity281 . Generation of reactive @entity26 species represents an important part of the inflammatory cascade in @entity295 . Dysregulation of @entity68 homeostasis can further promote the generation of radicals and amplify the damage caused by systemic immune activation. This can potentially be suppressed or prevented by @entity68 chelation. Therefore, this study was designed to examine the effects of a novel @entity68 chelator (DIBI) with or without standard antibiotic treatment in @entity694 ( @entity694 )-induced experimental @entity295 . METHODS: Six groups of animals (n  =  7-10) were included in the study: sham surgery; untreated @entity694 animals; @entity694 and subcutaneous (sc) or intraperitoneal DIBI administration, respectively; @entity694 and @entity2892 sc; and combination of DIBI and @entity2892 sc. RESULTS: We observed a 55% reduction in leukocyte adhesion in V1 venules after sc administration of DIBI and a 40% reduction after @entity2892 treatment, when compared to untreated @entity694 animals (P  <  0.05). A further reduction in the number of adherent leukocytes in V1 venules has been observed after combined treatment with DIBI and @entity2892 (66%). A significant decrease in bacterial count was observed from 2200 (150-64,000) to 100 (1-420) colony forming units per milliliter in blood in the sc DIBI and @entity2892 combination group (P  =  0.0065). The bacterial count in the peritoneal lavage fluid was also significantly reduced in the sc @entity2892 group and the sc DIBI and @entity2892 combination group (P  =  0.0021 and P  =  0.0001, respectively) when compared to untreated @entity694 animals. CONCLUSIONS: These findings suggest a potential role of @entity68 chelators in the treatment of @entity295 .

title: Anti-inflammatory and anti-bacterial effects of @entity68 chelation in experimental XXXX .

entities_list: @entity2892 :: ('MESH:D015378', 'Chemical') :: ['imipenem']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon ascendens stent peritonitis', 'CASP']

answer: @entity295 :: (MESH:D018805,Disease) :: ['sepsis']


abstract: A total of 115 @entity1 (29 with stage A1 and 86 with stage A2 @entity263 ) underwent radical retropubic prostatectomy. @entity5 was found in the radical prostatectomy specimen in 11 of the 29 stage-A1 @entity1 (38%) and in 66 of the 86 stage-A2 @entity1 (77%). 14% of the stage-A1 @entity1 and 29.5% of the stage-A2 @entity1 had pathological evidence of disease extension beyond the confined prostate. No perioperative @entity204 occurred and no @entity1 suffered @entity130 or was totally incontinent. Early @entity260 occurred in 6 @entity1 (5%). There were no late complications. Complete urinary control was achieved in 111 @entity1 (96.5%) and stress @entity322 was present in 4 @entity1 (3.5%). Sexual function was preserved in 21 of the 26 @entity1 (81%) who underwent a nerve-sparing radical prostatectomy. Follow-up ranged from 12 to 84 months with a mean of 30 months. All @entity1 are alive, and only 3 @entity1 suffered disease progression. These 3 @entity1 were among the stage-A2 group and had pathological evidence of @entity5 extension beyond the prostatic capsule. 26 @entity1 who also had evidence of disease extension are alive without evidence of disease. These data demonstrate that @entity1 with stage-A disease are at risk for disease progression if left untreated and, with morbidity as low as achieved in our series, radical prostatectomy should remain an optimal option for @entity5 control in these @entity1 .

title: Radical prostatectomy in the management of stage-A XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Residual cancer']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['rectal injury']

answer: @entity263 :: (MESH:D011471,Disease) :: ['carcinoma of the prostate']


abstract: PURPOSE: The inhibition of @entity9459 blocks mitochondrial membrane permeability transition (mMPT) for HLE-B3 cells in atmospheric oxygen. @entity9459 , as part of a multifactorial complex, also regulates nuclear levels of @entity3546 , a known coordinator of cell survival and adhesion. The purpose of these studies was to demonstrate a novel, but likely disadvantageous, link between @entity3546 's influence on the expression of the pro-survival protein, @entity7 ( @entity7 ), resulting in enhanced lens epithelial cell mitochondrial protection against depolarization and nuclear @entity3546 as an inducer of epithelial to mesenchymal transition (EMT). METHODS: Virally transformed @entity1 lens epithelial cells (HLE-B3) were treated with @entity25650 , a specific inhibitor of @entity9459 catalytic activity and @entity9949 , a specific @entity3546 inhibitor that bars the translocation of @entity3546 from cytoplasm to the nucleus. Western blot analysis was employed to detect the levels of cytoplasmic and nuclear @entity3546 and phospho- @entity3546 , pBcl-2 and the EMT proteins, @entity1970 ( @entity1970 ), and fibronectin. ELISA was used to measure the levels of @entity7 in cell culture supernatants. JC-1 analysis was performed to analyze the influence of either @entity25650 or @entity9949 on mitochondrial depolarization. RESULTS: Cultured lens epithelial cells maintained in @entity519 (1% oxygen) and subsequently reintroduced into atmospheric oxygen and treated with the @entity9459 inhibitor @entity25650 illustrated a marked inhibition of phosphorylation of glycogen synthase (downstream substrate of @entity9459 ) and significant increase in nuclear translocation of @entity3546 . The augmented nuclear @entity3546 levels positively correlated with increased expression of @entity1970 and fibronectin, both marker proteins indicative of EMT. The enhanced nuclear @entity3546 activity also elicited increased @entity7 and pBcl-2 expression, resulting in increased resistance to mitochondrial depolarization. Treatment of the cells with the @entity3546 inhibitor @entity9949 resulted in decreased expression of nuclear @entity3546 , @entity7 levels, pBcl-2, and EMT proteins, as well as increased mitochondrial depolarization. CONCLUSIONS: The data support a model whereby the onset of epithelial to mesenchymal transition may circuitously benefit from the enhanced synthesis of @entity7 by setting up a potentially harmful situation whereby the resulting mesenchymal cell population may be more resistant to mitochondrial depolarization than the lens epithelial cell population from which it originated. These findings support the potential therapeutic relevance of developing strategies to undermine the progression of normal cells to mesenchymal transition without subverting cell viability.

title: Lenticular cytoprotection, part 2: Link between XXXX , epithelial to mesenchymal transition, and mitochondrial depolarization.

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity1970 :: ('58', 'Gene') :: ['a-smooth muscle actin', 'a-SMA']

answer: @entity9459 :: (2932,Gene) :: ['glycogen synthase kinase-3b']


abstract: OBJECTIVES: We previously showed that an angiotensin-converting enzyme inhibitor ( @entity3371 ) or an angiotensin receptor blocker ( @entity9886 ) reduced @entity1188 size and improved endothelial function in a @entity35 model of ischaemia-reperfusion. The present study was undertaken to see if @entity117 ( @entity1281 ) antagonised the beneficial effects of @entity3371 or @entity9886 . METHODS: One hundred and fourteen @entity35 were randomised into six groups; Control, @entity1281 , @entity3371 , @entity9886 , @entity1281 + @entity3371 , and @entity1281 + @entity9886 . @entity1281 , @entity3371 or @entity9886 were given at a concentration of 40 mg/kg/day in drinking water. After six weeks of pre-treatment, the @entity35 were subjected to 17 minutes of left anterior descending @entity1563 and 120 minutes of reperfusion, with haemodynamic and ECG monitoring. During the reperfusion period, the effective refractory period (ERP), @entity2224 threshold (VFT) and bleeding time (BT) were measured. In fresh aortic rings precontracted with @entity2647 , endothelium-dependent and -independent relaxations were assessed using @entity934 and @entity1242 . RESULTS: Haemodynamic changes were not different between the groups. Serum @entity1281 concentrations were 0.5, 1.1 and 0.6 mg/dl in the @entity1281 , @entity1281 + @entity3371 and @entity1281 + @entity9886 groups, respectively, and BT was prolonged (p<0.01). @entity1281 alone reduced endothelium-dependent relaxation (-29+8 vs. -69+11%, p<0.01), but did not change endothelium-independent relaxation. @entity1281 did not affect endothelial relaxation induced by @entity934 in the presence of either @entity3371 or @entity9886 . @entity4689 and ERP were elevated by @entity3371 and @entity9886 . @entity1808 and VFT were elevated by @entity9886 . @entity1281 with @entity3371 , @entity3371 and @entity9886 equally reduced @entity1188 size, compared with control (39+3, 39+4, and 39+5 vs. 53+3%, all p<0.05). CONCLUSIONS: @entity3371 and @entity9886 had similar cardiovascular protective effects in a @entity35 model of ischaemia-reperfusion. @entity117 did not attenuate the cardiovascular protective effects of @entity3371 or @entity9886 .

title: Comparative effects of XXXX with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.

entities_list: @entity4689 :: ('MESH:D000803', 'Chemical') :: ['Angiotensin I']

entities_list: @entity1242 :: ('MESH:D005996', 'Chemical') :: ['nitroglycerin']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin']

entities_list: @entity1563 :: ('MESH:D054059', 'Disease') :: ['coronary artery occlusion']

entities_list: @entity3371 :: ('CHEBI:3380', 'Chemical') :: ['Captopril', 'captopril']

entities_list: @entity9886 :: ('MESH:D019808', 'Chemical') :: ['losartan']

entities_list: @entity2647 :: ('MESH:D010656', 'Chemical') :: ['phenylephrine']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity117 :: (MESH:D001241,Chemical) :: ['aspirin']


abstract: PURPOSE: @entity28 is commonly associated with poor sleep, @entity25 ( @entity25 ) and @entity308 mood but the impact of bariatric surgery on these conditions is incompletely understood. This study aimed to investigate the course of @entity25 and @entity25 in bariatric surgery @entity1 in relation with changes in body weight and @entity308 . METHODS: In @entity1 consecutively submitted to bariatric surgery, baseline and @entity86 were evaluated by the Pittsburgh Sleep Quality Index (PSQI), @entity25 by the Epworth Sleepiness Scale (ESS), risk for OSA by the Berlin Questionnaire (BQ), and @entity308 by the Beck Depression Inventory-Short Form (BDI). Comorbidities were assessed by interview and chart review. RESULTS: Sixty @entity1 (M/F  =  9/51) with a mean (  SD) age of 34.7      9.2  years and body mass index (BMI) of 46.04      7.52  kg/m(2) were studied. Bariatric surgery improved PSQI score (6.4      3.8 versus 4.1      2.8; p  <  0.001), ESS score (8.1      4.7 versus 6.0      3.3; p  <  0.001), BDI score (9.8      7.0 versus 4.7      4.6; p  =  0.001), and risk for OSA (68.3 versus 5%). Twelve of the 18 subjects with baseline @entity25 (ESS  >=   10) developed normal ESS score after surgery. In these subjects, significant postoperative improvement in @entity308 score was observed (12.0      9.0 versus 5.5      5.0; p  =  0.041), in contrast to the remaining six cases with persistent @entity25 , who showed no significant change in these symptoms (5.5      5.0 versus 3.2      3.1; p  =  0.416). CONCLUSION: Bariatric surgery has a beneficial effect on @entity25 and @entity25 . Postoperative improvement in @entity25 can be related to a @entity308 .

title: XXXX , Hypersomnolence, and Quality of Sleep: the Impact of Bariatric Surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms', 'depressive', 'reduction in depressive symptoms']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative sleep quality']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep quality', 'excessive daytime sleepiness', 'EDS']

answer: @entity28 :: (MESH:D009765,Disease) :: ['Obesity']


abstract: UNASSIGNED: Critical care and intensive care units (ICUs) have undergone dramatic changes and improvements in recent years, and critical care is today one of the fastest growing hospital disciplines. Significant improvements in treatments, removal of inefficient and harmful interventions, and introduction of advanced technological support systems have improved survival among critically ill ICU @entity1 . However, the improved survival is associated with an increased number of @entity1 with complications related to modern critical care. Severe @entity2057 and @entity121 are frequently observed in immobilized and mechanically ventilated ICU @entity1 . Approximately 30% of mechanically ventilated and immobilized ICU @entity1 for durations of five days and longer develop generalized @entity4589 of all limb and trunk muscles. These @entity1 typically have intact sensory and cognitive functions, a condition known as @entity3124 ( @entity3124 ). Mechanical ventilation is a lifesaving treatment in critically ill ICU @entity1 ; however, the being on a ventilator creates @entity734 , and the weaning process occupies as much as 40% of the total time of mechanical ventilation. Furthermore, 20% to 30% of @entity1 require prolonged intensive care due to ventilator-induced @entity409 (VIDD), resulting in poorer outcomes, and greatly increased costs to health care providers. Our understanding of the mechanisms underlying both @entity3124 and VIDD has increased significantly in the past decade and intervention strategies are presently being evaluated in different experimental models. This short review is restricted @entity3124 and VIDD pathophysiology rather than giving a comprehensive review of all acquired @entity2057 conditions associated with modern critical care.    2017 American Physiological Society. Compr Physiol 7:105-112, 2017.

title: @entity3124 ( XXXX ) and Ventilator-Induced Diaphragm Muscle Dysfunction (VIDD): Acquired @entity121 Affecting Contractile Proteins.

entities_list: @entity4589 :: ('MESH:D012133', 'Disease') :: ['muscle paralysis']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['CIM', 'critical illness myopathy']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['diaphragm dysfunction']

entities_list: @entity2057 :: ('MESH:D009133', 'Disease') :: ['muscle wasting']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['impaired muscle function']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']

answer: @entity3124 :: (MESH:D016638,Disease) :: ['CIM']


abstract: OBJECTIVE: To review the role of @entity8 in our unit, assessing the indications, tolerability and efficacy of this technique for treating @entity1358 ( @entity1358 ). @entity1 AND METHODS: Thirty @entity1 undergoing transarterial embolization between 1991 and 1999 were identified and 25 case notes analysed retrospectively. RESULTS: Most @entity1 (14 of 25) presented with less advanced (stage I-III) @entity1358 who were unable or unwilling to undergo radical surgery; the remainder (11) presented with advanced (stage IV) disease. The embolizing agent was @entity1068 , usually combined with stainless steel coils (85% of cases). Procedural @entity158 and @entity221 was controlled successfully. The median hospital stay associated with the procedure was 4 days. At the time of analysis six of 11 stage IV and 11 of 14 stage I-III @entity1 were alive (median follow-up 27 and 39 months, respectively). Symptoms from the primary @entity5 were well controlled. Overall, 17 of 25 (68%) of @entity1 reported no problems while three (12%) required brief hospital admission for treatment of persistent haematuria. Fourteen @entity1 were subsequently re-staged; the primary @entity5 in two had increased, in seven remained unchanged and in five it decreased. No @entity1 without @entity3 developed them and @entity3 in two @entity1 regressed. CONCLUSION: Transarterial embolization is associated with minimal morbidity and complications, and subsequent symptom control is good. The effect of palliative embolization on @entity1358 progression is unknown and requires prospective investigation. Presently, there is no role for cytoreductive embolization; it should be included as a treatment option in clinical trials evaluating such options in @entity1 with metastatic @entity1358 .

title: The role of transarterial embolization in the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['transarterial renal embolization']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']


abstract: UNASSIGNED: 4096 Background: Combinations of @entity136 ( @entity14113 )/ @entity1487 , @entity14113 / @entity901 (LOHP) or @entity1487 /LOHP work synergistically in pancreatic and/or @entity14 , and have non-overlapping safety profiles. This phase II-study was designed to evaluate the efficacy and safety of the triple combination @entity14113 /LOHP/ @entity1487 in @entity1 (pts) with advanced @entity788 . METHODS: Eligibility criteria: chemonaive pts with histologically proven advanced, recurrent or metastatic @entity788 (ECOG 0-1: expected survival >3 months: measurable disease: adequate renal, hepatic and @entity236 ). According to the results of our phase I-study (Proc ASCO 2003, p 1298),pts were treated with @entity14113 900mg/m(2) as a 30-min infusion, followed by LOHP (2-hr infusion) after a 30 min rest and @entity1487 (24-hr-infusion) on d 1, 8, then every 3 weeks. The primary endpoint was @entity5 response, secondary endpoints were survival, time to progression, @entity137 , clinical benefit and quality of life. RESULTS: 45 pts enrolled, median follow up is 5.6 months. Pt. characteristics: m/f 31/14, median age 63 (range 45-74), ECOG 0/1 20/25, locally advanced/metastatic disease 18/27 pts. (40/60%). Median survival of all pts is 7.4 months (95% CI: 4.3-9.9). Currently 169 cycles in 32 pts. can be evaluated for @entity137 : grade III/ IV (NCI-CTC) @entity137 occurred in 23.4/ 3% of cycles and were @entity1210 1.8/ 0%, @entity882 3/ 0%, @entity417 2.4/ 0 %, @entity390 3.6/ 0%, emesis 0.6/ 0%, anorexia 3/ 1.8%, fatigue 1.2/ 0.6%, elevated @entity648 2.4/ 0.6% or AP 2.4/ 0%, @entity715 / @entity887 1.2/ 0 %, somnolence 0.6/ 0%, @entity4053 0.6/ 0%. Analysis of response is still pending. CONCLUSIONS: The @entity14113 /LOHP/ @entity1487 combination is tolerated well. The current survival is promising, but has to be confirmed in a phase III study. (Supported by grants from Eli Lilly and Company, Indianapolis, IN, USA and Sanofi-Synthelabo, Paris, France) No significant financial relationships to disclose.

title: XXXX , @entity901 and weekly high-dose @entity1487 as a 24-hr-infusion in chemonaive @entity1 with advanced or metastatic @entity788 : preliminary results of a multicenter phase II-study.

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic adenocarcinoma']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal malignancies']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow function']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']

entities_list: @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']


abstract: BACKGROUND: Despite the high risk for @entity1 harm during unanticipated ICU evacuations, critical care providers receive little to no training on how to perform safe and effective ICU evacuations. We reviewed the pertinent published literature and offer suggestions for the critical care provider regarding ICU evacuation. The suggestions in this article are important for all who are involved in pandemics or disasters with multiple critically ill or injured @entity1 , including front-line clinicians, hospital administrators, and public health or government officials. METHODS: The Evacuation and Mobilization topic panel used the American College of @entity764 ( @entity764 ) Guidelines Oversight Committee's methodology to develop seven key questions for which specific literature searches were conducted to identify studies upon which evidence-based recommendations could be made. No studies of sufficient quality were identified. Therefore, the panel developed expert opinion-based suggestions using a modified Delphi process. RESULTS: Based on current best evidence, we provide 13 suggestions outlining a systematic approach to prepare for and execute an effective ICU evacuation during a disaster. Interhospital and intrahospital collaboration and functional ICU communication are critical for success. Pre-event planning and preparation are required for a no-notice evacuation. A Critical Care Team Leader must be designated within the Hospital Incident Command System. A three-stage ICU Evacuation Timeline, including (1) no immediate threat, (2) evacuation threat, and (3) evacuation implementation, should be used. Detailed suggestions on ICU evacuation, including regional planning, evacuation drills, @entity1 transport preparation and equipment, @entity1 prioritization and distribution for evacuation, @entity1 information and tracking, and federal and international evacuation assistance systems, are also provided. CONCLUSIONS: Successful ICU evacuation during a disaster requires active preparation, participation, communication, and leadership by critical care providers. Critical care providers have a professional obligation to become better educated, prepared, and engaged with the processes of ICU evacuation to provide a safe continuum of critical care during a disaster.

title: Evacuation of the ICU: Care of the Critically Ill and Injured During Pandemics and Disasters: XXXX Consensus Statement.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity764 :: ('MESH:D013898', 'Disease') :: ['Chest Physicians', 'CHEST']

answer: @entity764 :: (MESH:D013898,Disease) :: ['CHEST']


abstract: BACKGROUND: Rituximab, a chimeric antibody directed against @entity2225 , has a high therapeutic value in refractory/relapsed low-grade or follicular B-cell @entity1893 as a monotherapy or in combination with polychemotherapy. OBJECTIVES: We sought to evaluate the clinical activity and @entity137 of a schedule foreseeing the use of intravenous @entity2408 preceded by single-dose @entity786 in the treatment of @entity1 with primary @entity1892 who progressed and relapsed after chemotherapy. METHODS: A total of 7 @entity1 were treated; 4 had both @entity75 and nodal or visceral involvement. All the @entity1 had been previously treated with at least 1 standard chemotherapy regimen, and 4 with 2 or more, with a median response duration of 8 months. Immunohistochemistry on frozen sections was performed with monoclonal antibodies directed against @entity2225 , @entity9819 , and @entity1009 before rituximab treatment. RESULTS: The overall objective response rate was 85.7%, with a complete response in 5 @entity1 ; treatment was well tolerated in all cases. After a median follow-up of 13 months, 2 @entity1 showed a cutaneous relapse. The response durations of the remaining @entity1 who were disease-free are now 5, 7, 17, and 18 months. No relationship was found between @entity9819 and @entity1009 expression and the clinical outcome. CONCLUSION: Although a longer follow-up period is needed to confirm these data, our results are encouraging, particularly in terms of disease-free survival.

title: Systemic therapy with XXXX and anti- @entity2225 antibody (rituximab) in relapsed primary @entity1892 : a report of 7 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2408 :: ('CHEBI:64357', 'Chemical') :: ['rituximab']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['cutaneous lesions']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['cutaneous B-cell lymphoma']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphomas"]

answer: @entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']


abstract: BACKGROUND: Malignant @entity2615 (MPM) is an aggressive @entity5 arising from mesothelial cells lining the @entity1143 characterized by resistance to standard therapies. Most of the molecular steps responsible for @entity1143 remain unclear; however, several growth factor signaling cascades are known to be altered during MPM onset and progression. Transducers of these pathways, such as @entity20721 , MAPK, and ezrin/radixin/moesin (ERM) could therefore be exploited as possible targets for pharmacological intervention. This study aimed to identify 'druggable' pathways in MPM and to formulate a targeted approach based on the use of commercially available molecules, such as the multikinase inhibitor @entity2857 and the @entity3470 inhibitor @entity2239 . METHODS: We planned a triple approach based on: i) analysis of immunophenotypes and mutational profiles in a cohort of thoracoscopic MPM samples, ii) in vitro pharmacological assays, ii) in vivo therapeutic approaches on MPM xenografts. No mutations were found in 'hot spot' regions of the @entity3470 upstream genes (e.g. @entity12841 , @entity11518 and @entity20721 ). RESULTS: Phosphorylated @entity3470 and ERM were specifically overexpressed in the analyzed MPM samples. @entity2857 and @entity2239 combination was effective in @entity3470 and ERM blockade; exerted synergistic effects on the inhibition of MPM cell proliferation; triggered ROS production and consequent AMPK-p38 mediated- apoptosis. The antitumor activity was displayed when orally administered to MPM-bearing NOD/ @entity915 @entity19 . CONCLUSIONS: ERM and @entity3470 pathways are activated in MPM and 'druggable' by a combination of @entity2857 and @entity2239 . Combination therapy is a promising therapeutic strategy against MPM.

title: The combination of XXXX and @entity2239 shows antitumor activity in preclinical models of malignant pleural mesothelioma.

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural transformation', 'pleural cavities']

entities_list: @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib', 'Sorafenib']

entities_list: @entity2615 :: ('MESH:D008654', 'Disease') :: ['Pleural Mesothelioma']

entities_list: @entity2239 :: ('MESH:C107135', 'Chemical') :: ['everolimus']

answer: @entity2857 :: (MESH:C471405,Chemical) :: ['sorafenib']


abstract: @entity311 afflicts around 200 million @entity1 annually, with a mortality number close to 600,000. The mortality rate in @entity1 @entity6197 (HCM) is unacceptably high (15-20%), despite the availability of @entity507 -based therapy. An effective adjunct therapy is urgently needed. Experimental @entity6197 (ECM) in @entity19 manifests many of the neurological features of HCM. Migration of T cells and parasite-infected RBCs (pRBCs) into the brain are both necessary to precipitate the disease. We have been able to simultaneously target both these parameters of ECM. @entity6108 alone was able to reverse all the parameters investigated in this study that govern inflammatory responses, @entity405 (+) T cell and pRBC sequestration into the brain and blood brain barrier (BBB) breakdown. But the animals eventually died of @entity417 due to parasite build-up in blood. However, arteether- @entity6108 (AC) combination therapy even after the onset of symptoms provided complete cure. AC treatment is a promising therapeutic option for HCM.

title: Simultaneously targeting inflammatory response and parasite sequestration in brain to treat Experimental XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Human', 'people']

entities_list: @entity6108 :: ('MESH:D003474', 'Chemical') :: ['Curcumin', 'curcumin']

entities_list: @entity507 :: ('MESH:C031327', 'Chemical') :: ['artemisinin']

entities_list: @entity6197 :: ('MESH:D016779', 'Disease') :: ['Cerebral Malaria']

answer: @entity6197 :: (MESH:D016779,Disease) :: ['Cerebral Malaria']


abstract: In 3-dimensional (3D) conformal radiotherapy of @entity5 , little effort is made to avoid the auditory system or the oral cavity. Damage may occur when the ear is located inside the treatment field. The purpose of this study was to design and evaluate an intensity-modulation radiotherapy (IMRT) class solution, and to compare this technique to a 3D conformal approach with respect to @entity393 . Twenty @entity1 with @entity5 were retrospectively planned with 2 different techniques using the original planning target volume ( @entity343 ). First, a conventional technique using a wedged beam pair was applied, yielding a dose distribution conformal to the shape of the @entity343 . Next, an IMRT technique using a fluence map optimization with predefined constraints was designed. A dose of 66 Gy in the @entity343 was given at the International Commission on Radiation Units and Measures (ICRU) dose prescription point. Dose-volume histograms of the @entity343 and organs at risk (OARs), such as auditory system, oral cavity, and spinal cord, were compared. The dose in the OARs was lower in the IMRT plans. The mean volume of the middle ear receiving a dose higher than 50 Gy decreased from 66.5% to 33.4%. The mean dose in the oral cavity decreased from 19.4 Gy to 16.6 Gy. The auditory system can be spared if the distance between the inner ear and the @entity343 is 0.6 cm or larger, and if the overlap between the middle ear and the @entity343 is smaller than 10%. The maximum dose in the spinal cord was below 40 Gy in all treatment plans. The mean volume of the @entity343 receiving less than 95% of the prescribed dose increased in the IMRT plan slightly from 3.3% to 4.3 % (p = 0.01). The mean volume receiving more than 107% increased from 0.9% to 2.5% (p = 0.02). It can be concluded that the auditory system, as well as the oral cavity, can be spared with IMRT, but at the cost of a slightly larger dose inhomogeneity in the @entity343 . The IMRT technique can therefore, in most cases, be recommended as the treatment of choice for the irradiation of @entity5 .

title: Intensity-modulated vs. conformal radiotherapy of XXXX : potential impact on @entity393 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['parotid gland tumors', 'parotid gland cancer', 'parotid tumors']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

answer: @entity5 :: (MESH:D009369,Disease) :: ['parotid gland tumors']


abstract: AIMS: The aim of this study was to investigate the interactive effect of physical training and chronic @entity1068 ingestion on changes in blood pressure (BP) and aortic reactivity response in @entity35 . METHODS: Male Fisher @entity35 were divided into four groups of seven animals each and treated as follows: (i) control (5% @entity969 , orally) daily for 12 weeks; (ii) @entity1068 (4 g kg(-1), orally) daily for 12 weeks; (iii) exercise training on treadmill followed by @entity969 daily for 12 weeks; (iv) exercise training on treadmill followed by @entity1068 daily for 12 weeks. The body weight and BP were recorded every week. The animals were anaesthetized with pentobarbital after 12 weeks; blood and thoracic aorta were isolated and analysed for @entity1068 and reactivity response using tissue bath technique, respectively. RESULTS: The data show that exercise training significantly lowered the weight gain 6-12 weeks in @entity1068 -treated @entity35 compared to @entity1068 alone or control @entity35 . The systolic and mean BP significantly elevated 6-12 weeks, whereas diastolic BP elevated 8-12 weeks after @entity1068 ingestion. Exercise training lowered the BP close to the normal control values in @entity1068 fed @entity35 . Blood @entity1068 level significantly elevated in @entity1068 group but decreased in exercise plus @entity167 group. Aortic contractile response to @entity2647 in @entity1068 or control groups was attenuated by training with or without intact endothelium. @entity1068 significantly reduced the aortic relaxation response to @entity934 whereas training enhanced the relaxation response with intact endothelium. The relaxation responses to @entity859 and @entity1854 in the aortic ring segments of @entity35 with or without endothelium were decreased in @entity1068 group which were attenuated by exercise training. CONCLUSIONS: Physical training attenuates the chronic @entity1068 -induced @entity101 via @entity353 , clearance of @entity1068 , and augmentation of the aortic endothelial relaxation response in @entity35 .

title: Physical training ameliorates chronic @entity167 -induced XXXX and aortic reactivity in @entity35 .

entities_list: @entity859 :: ('MESH:D000241', 'Chemical') :: ['adenosine']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['reduction of body weight']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity2647 :: ('MESH:D010656', 'Chemical') :: ['phenylephrine']

entities_list: @entity1068 :: ('MESH:D000431', 'Chemical') :: ['Ethanol', 'ethanol']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: The @entity235 right atrium was perfused with arterial blood led from a carotid artery of the heparinized support @entity235 and suspended in a bath filled with blood. In 5 non-spontaneously beating preparations, the frequency-force relationship was investigated by electric stimulation at a frequency range from 0.017 to 3 Hz. At a low frequency level, a large peak @entity2701 developed. At 0.5 Hz, minimum values of developed @entity2701 were obtained. At a range of 0.5-3 Hz, the developed @entity2701 increased with the frequency. Higher frequencies than 4 Hz usually caused pulsus alternans. The staircase phenomena were not influenced by treatment with @entity1169 or @entity3897 . Therefore, there may be no participation of the autonomic nerve stimulation on the frequency-force relationship. Effects of @entity4485 , (+/-)- @entity1855 and @entity921 on the frequency-force relationship were investigated with both the blood-perfused, isolated atrium preparations and isolated ventricular preparations. @entity4485 and @entity13718 produced a uniform @entity308 of the developed @entity2701 at all frequencies but the @entity308 with (+/-)- @entity1855 was greater at higher frequencies in both @entity121 .

title: Effect of @entity4485 , @entity1855 and XXXX on the frequency-force relationship of the isolated atrium and ventricle of the @entity235 heart.

entities_list: @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol']

entities_list: @entity4485 :: ('MESH:D010424', 'Chemical') :: ['pentobarbital', 'Pentobarbital']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity921 :: ('MESH:D008345', 'Chemical') :: ['manganese']

entities_list: @entity1855 :: ('MESH:D014700', 'Chemical') :: ['verapamil']

entities_list: @entity13718 :: ('MESH:C025340', 'Chemical') :: ['manganese chloride']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['atrial and ventricular muscles']

answer: @entity921 :: (MESH:D008345,Chemical) :: ['manganese']


abstract: @entity4530 of the lung is suggested as a risk factor for @entity2 . Here we report a case with @entity2 in @entity4530 , which showed rapid progression. A 57-year-old @entity1 , who had a history of heavy smoking, was admitted to our hospital due to hemoptysis. A chest X-ray revealed @entity4530 with a ground glass shadow and a high fluid level in the right upper lung. Sputum cytology was negative for malignant cells. A chest X-ray a month later showed increases of the size of the radio-opaque shadow and of the air-fluid retention, suggesting @entity548 from the @entity4530 . Limited resection or lobectomy was indicated, but pneumonectomy was performed due to the severe air-leak. Macroscopically, a @entity5 arose from the bulla wall, which might be related to blood flow and @entity39 tissue. The postoperative pathological diagnosis was @entity4937 . Unfortunately, the @entity1 developed a recurrence of @entity189 in the @entity6675 and died at 2.5 months after the operation. Based on this report and review of other cases in the literature, we should keep in mind the rapid progression of @entity2 in association with an @entity4530 .

title: XXXX associated with a pulmonary giant bulla: a case report.

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['pulmonary hemorrhage']

entities_list: @entity4530 :: ('MESH:D001768', 'Disease') :: ['A giant bulla', 'emphysematous bulla', 'a giant bulla', 'giant bulla']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['multiple nodular tumor']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity4937 :: ('MESH:D000231', 'Disease') :: ['papillary adenocarcinoma']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity6675 :: ('MESH:D020139', 'Disease') :: ['pleuroperitoneal cavity']

answer: @entity2 :: (MESH:D008175,Disease) :: ['Rapid-growth lung cancer']


abstract: BACKGROUND: Considering the limited cross protection offered by the current HPV vaccines, understanding the HPV genotype distribution among the different population is essential in predicting the efficacy of current vaccine and devising new vaccine strategy. The present work aimed at investigating the HPV genotypes distribution among @entity1 with and without @entity2622 in Odisha, Eastern India. METHODS: A total of 607 @entity1 have been enrolled between January 2014 and June 2016. L1-PCR, sequencing, and E6/E7 nested multiplex type- specific PCR were performed for HPV detection and genotyping. Cytological distribution of 440 cases includes @entity189 or @entity3 (n   =   210), inflammatory smear (n   =   162), normal cytology (n   =   68). Statistical analyses were performed by using SPSS version 20.0 software and MediCal version 14.10.2(7). A p-value of   <=    0.05 was considered statistically significant. RESULTS: The overall prevalence of @entity281 was (359/595) 60.33%. Prevalence of @entity281 was 93.80% (197/210) in @entity3 ( @entity3 ) cases, 54.32% (88/162) in inflammatory smear and 19.11% (13/68) in normal cervical cytology. The most prevalent genotype was @entity1799 (87.28%) followed by HPV18 (24.56%) and HPV 51(3.46%). The overall prevalence of single type was 76.58% and highest (78.9%) among @entity3 cases. The most frequent genotype combination after @entity1799   +   18(9.4%) was @entity1799   +   66   +   68(2.7%) which was frequently observed in inflammatory cytology. Age   >   45years, parity >= 3, low socio-economic condition, rural residential area and post menopause state were significantly associated with @entity281 . @entity281 did not have a significant association with any of the clinicopathological variables (stage, LN @entity3 , cell type) except @entity5 size   >=    2cm in @entity3 cases. The impact of 2v, 4v, and 9v vaccines in preventing @entity5 in Odisha were 89.99, 91.65, and 92.16% respectively. CONCLUSION: This data would help planning an appropriate strategy for disease monitoring and provides baseline data for post-vaccination surveillance in the region. The nonavalent vaccine would be significant in preventing @entity2622 in Odisha. Hence an effective vaccination program based on regional HPV epidemiological profile along with the @entity5 screening is necessary to reduce the @entity5 burden in India.

title: HPV Genotypes distribution in Indian @entity1 with and without XXXX : Implication for HPV vaccination program in Odisha, Eastern India.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer']

entities_list: @entity2622 :: ('MESH:D002583', 'Disease') :: ['cervical carcinoma']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['invasive cervical carcinoma']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['Multiple infections', 'HPV infection']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'ICC', 'invasive cervical cancer']

answer: @entity2622 :: (MESH:D002583,Disease) :: ['cervical carcinoma']


abstract: Inflammatory cells are postulated to mediate some of the @entity75 following @entity385 . @entity1779 is associated with more @entity32 than @entity385 . We tested the sulfated polysaccharide @entity29947 , which has been reported to reduce inflammatory @entity75 , in a @entity35 model of @entity1779 induced by injection of bacterial collagenase into the caudate nucleus. @entity35 were treated with seven day intravenous infusion of @entity29947 (30 micrograms h-1) or vehicle. The @entity1410 was assessed in vivo by magnetic resonance imaging. Motor behavior, passive avoidance, and skilled forelimb function were tested repeatedly for six weeks. @entity29947 -treated @entity35 exhibited evidence of @entity4461 and hemodilution, had larger @entity1410 , and tended to have less @entity32 in the vicinity of the @entity1410 after three days. They showed significantly more rapid improvement of motor function in the first week following @entity548 and better memory retention in the passive avoidance test. Acute @entity4 and eventual @entity528 in the striatum adjacent to the @entity1410 did not differ between the two groups. Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in @entity1779 .

title: Effect of XXXX treatment on collagenase-induced @entity1779 in @entity35 .

entities_list: @entity29947 :: ('MESH:C007789', 'Chemical') :: ['Fucoidan', 'fucoidan']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain damage']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['white matter edema']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas', 'hematoma']

entities_list: @entity4461 :: ('MESH:D020141', 'Disease') :: ['impaired blood clotting']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal loss']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hemorrhage', 'Intracerebral hemorrhage']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity29947 :: (MESH:C007789,Chemical) :: ['fucoidan']


abstract: BACKGROUND: Thymectomy is considered the most effective treatment for achieving sustained improvement as well as remission in @entity1 with @entity1737 ( @entity1737 ), and most neurologists favor the use of this procedure. The main focus of many current studies is to determine response-predicting factors. METHODS: Clinical records of 152 @entity1 with an established diagnosis of @entity1737 who underwent thymectomy at our institution were reviewed. The purpose was to evaluate outcome of surgical management for @entity1737 and prognostic factors that influence that outcome. RESULTS: The majority of @entity1 were @entity1 (119 of 152); mean age was 32.10 +/- 14.42 years, while time elapsed from diagnosis to surgery was 20.67 +/- 19.7 months. Transsternal thymectomy was performed on 113 @entity1 and transcervical on 39. Forty percent of @entity1 achieved remission and 28% showed improvement; with this, a good response to thymectomy was seen in 68% of @entity1 (n = 103). The most important variables associated with remission were <60 years of age, <2 years of preoperative symptoms, and use of @entity4836 at low doses. Factors related with poor response were >60 years of age, preoperative Osserman stage other than II, use of high doses of @entity4836 , use of @entity288 , and presence of thymic atrophy or @entity704 in histopathologic analyses. There was no mortality, although 20 @entity1 (13%) presented complications. CONCLUSIONS: Mexican @entity1 with @entity1737 undergoing thymectomies show improvement and remission rates similar to those reported by other studies. Age, length of symptoms, thymic pathology, and medications appear to be predictors of response to thymectomy for @entity1737 .

title: Thymectomy in XXXX : response, complications, and associated conditions.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity4836 :: ('MESH:D011729', 'Chemical') :: ['pyridostigmine']

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['MG', 'myasthenia gravis']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity1737 :: (MESH:D009157,Disease) :: ['myasthenia gravis']


abstract: UNASSIGNED: Molecular @entity26 ( @entity3612 ) is key to all life on earth, as it is constantly cycled via photosynthesis and cellular respiration. Substantial scientific effort has been devoted to understanding every part of this cycle. Classical @entity74 ( @entity74 ) simulations have been used to study some of the key processes involved in cellular respiration: @entity3612 permeation through alveolar monolayers and cellular membranes, its binding to hemoglobin during transport in the bloodstream, as well as its transport along optimal pathways toward its reduction sites in proteins. Moreover, @entity74 simulations can help interpret the results of several imaging techniques in which @entity3612 is used because of its paramagnetic nature. However, despite the widespread use of computational models for the @entity3612 molecule, their performances have never been systematically evaluated. In this paper, we assess the performances of 14 different models of @entity3612 available in the literature by calculating four thermodynamic properties: density, heat of vaporization, free energy of hydration, and free energy of solvation in @entity2291 . For each property, reliable experimental data are available. Most models perform reasonably well in predicting the correct trends, but they fail to reproduce the experimental data quantitatively. We then develop new models for @entity3612 , with and without a quadrupole moment, and compare their behavior with the behavior of previously published models. The new models show significant improvement in terms of density, heat of vaporization, and free energy of hydration. However, quantitative agreement with water-oil partitioning is not reached due to discrepancies between the calculated and measured free energies of solvation in @entity2291 . We suggest that classical pairwise-additive models may be inadequate to properly describe the thermodynamics of solvation of apolar species, such as @entity3612 , in apolar solvents.

title: On Atomistic Models for Molecular XXXX .

entities_list: @entity2291 :: ('MESH:C007932', 'Chemical') :: ['hexadecane']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['molecular dynamics', 'MD']

answer: @entity26 :: (MESH:D010100,Chemical) :: ['Oxygen']


abstract: PURPOSE: To delineate the relevance of pelvic and para-aortic node involvement in optimally cytoreduced ( @entity5 <1 cm) @entity43 @entity1 . METHODS: Ninety-five consecutive optimally cytoreduced (R  <= 1 cm) @entity1 with @entity43 underwent stage-related surgery and got adjuvant @entity902 -based chemotherapy. Median follow-up: 53.5 months. All @entity1 got systematic lymphadenectomy. On average, 24.7 pelvic and para-aortic lymph nodes were removed per @entity1 (range 1-60 nodes). @entity1 were stratified into three groups to evaluate node involvement (ratio: affected to resected nodes): (1) (=0); (2) (>0- <= 0.5) >0 and  <= 50 % of affected nodes; (3) (>0.5- <= 1) >50 % of affected nodes. Clinical parameters were retrospectively evaluated. Kaplan-Meier survival curve was used to evaluate the prognostic value. RESULTS: Most often serous histology, histologic grade 3 and a node ratio >0- <= 0.5 (61.1 %) were detected. Complete cytoreduction (R = 0 mm) has significant best prognostic impact compared to R > 0 mm-1 cm ( @entity3012 : p = 0.047, PFS: p = 0.00). Node involvement was associated with serous histology and grade 3. Increasing node ratio leads to significant decreased @entity3012 (p = 0.019) and significant best @entity3012 was associated with node ratio >0- <=0.5. CONCLUSIONS: The goal is optimal cytoreduction in advanced @entity43 . More extensive lymphadenectomy seems to play an important role in providing an accurate staging, and the node ratio might give prognostic information. Current prospective studies like the LION study (AGO-Ovar) had to investigate if these data have therapeutic implications and may be considered in future staging.

title: The prognostic relevance of node metastases in optimally cytoreduced advanced XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'stage IIIC ovarian cancer', 'primary stage IIIc ovarian cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['residual tumour']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: BACKGROUND: Although severe @entity73 is believed to occur commonly in complicated @entity3673 , the relationships of @entity7864 (CWP) to pulmonary function and @entity1576 have remained under debate. The study aims to investigate if @entity3673 is associated with significant @entity73 and increased risk of @entity1576 . METHODS: Spirometry and diffusing capacity were performed in 205 miners with simple CWP and 289 without X ray evidence of @entity3673 , who were selected from a large underground coal mine in China. A questionnaire on occupational history and @entity1576 including breathlessness, chronic cough, and phlegm was administered. The presence or absence of @entity2415 on their X-ray films was also evaluated. Logistic regression and multiple linear regression analysis were applied to estimate the independent effect of CWP on @entity1576 and parameters of pulmonary function. RESULTS: On the average, the miners with CWP had lower values of pulmonary function and higher prevalences of @entity1576 , and @entity2415 than did those without. The simple CWP was associated with increased risk of the @entity1576 after adjusting for age, smoking, and years underground. Regression analysis showed that the CWP had significantly independent effects on parameters of pulmonary function. Even when the effects of @entity2415 , @entity1576 indicating chronic @entity3617 were taken into consideration, the significant relationship between CWP and decrements in FVC and diffusing capacity remained. CONCLUSION: The findings of this study are consistent with simple CWP being a contributor to significant decrements in pulmonary function, and to increased risk of @entity1576 .

title: Respiratory symptoms and pulmonary function in coal miners: looking into the effects of XXXX .

entities_list: @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis']

entities_list: @entity7864 :: ('MESH:D055008', 'Disease') :: ["simple coal workers' pneumoconiosis"]

entities_list: @entity3673 :: ('MESH:D011009', 'Disease') :: ['pneumoconiosis', 'simple pneumoconiosis']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment of pulmonary function']

entities_list: @entity2415 :: ('MESH:D004646', 'Disease') :: ['emphysema']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory symptoms']

answer: @entity3673 :: (MESH:D011009,Disease) :: ['simple pneumoconiosis']


abstract: OBJECTIVE: The objective of this study was to investigate the effectiveness of radiation therapy as a treatment for brain @entity3 from @entity1204 . METHODS: Between July 1985 and November 1999, 10 @entity1 with brain @entity3 from @entity1204 were treated at the Cleveland Clinic. We reviewed the @entity1 and @entity5 characteristics at the time of the primary diagnosis and the brain @entity3 diagnosis. For the 8 @entity1 who received radiation therapy with or without surgery, we analyzed the treatment results with regard to survival and local control of the @entity3 . RESULTS: Brain @entity3 from @entity1204 were commonly accompanied by uncontrolled local-regional disease and systemic @entity3 . @entity75 developed in 7 of 10 @entity1 . Two @entity1 were treated with surgery alone and had a median survival of 2.75 months (4 and 1.5 months) after the brain @entity3 diagnosis. Three @entity1 were treated with surgery and radiation therapy and lived for a median survival of 15 months (range 11.5 to 15.5 months). The 5 @entity1 who were treated with radiation therapy without surgery had a median survival of 2.4 months (range 0.25 to 6 months). @entity1 with multiple brain @entity3 had a shorter survival than @entity1 with a single @entity3 . CONCLUSION: Overall survival after brain @entity3 development in @entity1 with @entity1204 was poor. Although the number of @entity1 was small, radiation therapy alone resulted in poor survival. Combination treatment with surgery and radiation therapy may improve survival for selected @entity1 .

title: The effect of radiation therapy on brain @entity3 from XXXX : a retrospective study.

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial carcinoma']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Multiple brain lesions']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['endometrial carcinoma']


abstract: BACKGROUND: High-dose therapy and autologous stem-cell transplant (HDT/ASCT) is the preferred treatment of chemosensitive relapsed/ @entity978 ( @entity978 ). The role for HDT/ASCT in chemoresistant @entity978 is less well defined. We evaluated long-term outcomes of relapsed/refractory @entity978 @entity1 whose disease was refractory to secondary chemotherapy preceding HDT/ASCT. @entity1 AND METHODS: All @entity978 @entity1 who underwent HDT/ASCT in British Columbia for primary progression (PP, defined as progression within 3 months of initial therapy completion) or first relapse (REL1) were reviewed. @entity1 were grouped based on response to secondary chemotherapy as sensitive (S), resistant (R), and untested/unknown (U). RESULTS: A total of 256 @entity1 underwent HDT/ASCT for PP (35%) or REL1 (65%) between 1985 and 2011. At median follow-up of 11.7 years, 58% were alive without @entity978 , 36% relapsed; 6% died of transplant-related mortality, 3% secondary @entity5 , and 3% unrelated causes. For PP/S, @entity11595 groups, 10-year FFS were 47%, 31%, and 38%; 10-year OS were 52%, 29%, and 37%, respectively. For REL1/S, REL1/R, and REL1/U groups, 10-year FFS were 64%, 51%, and 81%; 10-year OS were 71%, 59%, and 79%, respectively. In multivariate analysis, resistance to secondary chemotherapy predicted for post-transplant mortality in the PP (P = 0.04) but not REL1 (P = 0.16) groups. CONCLUSION: In this large uniformly treated cohort of @entity978 @entity1 with long-term follow-up, chemoresistance preceding HDT/ASCT was identified as a poor prognostic factor; however, this factor can be partially overcome by HDT/ASCT, resulting in cure in 30%-50% of @entity1 . HDT/ASCT should therefore be considered in all transplant eligible @entity1 , regardless of responsiveness to salvage chemotherapy.

title: Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and XXXX   .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'refractory Hodgkin lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

answer: @entity978 :: (MESH:D006689,Disease) :: ['refractory Hodgkin lymphoma']


abstract: BACKGROUND AND OBJECTIVE: To determine the prevalence of @entity7446 ( @entity7446 ) and work-exacerbated @entity565 (WEA) among @entity748 @entity1 diagnosed in Primary Health Care (PHC). To analyze the impact at PHC level caused by under-diagnosis and inappropriate referral of @entity7446 . @entity1 AND METHODS: A descriptive, cross-sectional multicenter study in @entity1 aged between 16 and 64years diagnosed with @entity565 , according to their medical record; all were working or had worked, and were assigned to one of 16 PHC centers in a healthcare district. Based on the responses to the questionnaire completed at the study visit, which included a thorough review of the subject's entire working history, @entity1 were classified into three categories by an expert in @entity7446 : @entity7446 , WEA or common @entity565 (CA). RESULTS: Three hundred and sixty-eight @entity1 completed the questionnaire. The prevalence of @entity7446 was 18.2% (25% in @entity1 and 14.6% in @entity1 , P=.046), and 54 @entity1 (14.7%) were classified as WEA. The proportion of @entity1 with work-related @entity565 (WRA) was therefore 32.9%. @entity748 @entity1 with WRA took more sick leave than CA @entity1 (P<.001). CONCLUSIONS: A high prevalence of WRA was found, mostly treated in PHC. Under-diagnosis of WRA is widespread in PHC.

title: Prevalence of Work-Related XXXX and its Impact in Primary Health Care.

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic', 'Asthmatic']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men']

entities_list: @entity7446 :: ('MESH:D059366', 'Disease') :: ['OA', 'occupational asthma']

answer: @entity565 :: (MESH:D001249,Disease) :: ['Asthma']


abstract: BACKGROUND: Morbidly @entity28 @entity1 are affected by @entity354 ( @entity354 ) and @entity357 ( @entity357 ) more frequently than lean @entity1 . Because of conflicting results, the indication to sleeve gastrectomy (SG) in @entity1 with @entity354 is still debated. OBJECTIVES: To evaluate the incidence of @entity354 on the basis of clinical, endoscopic, and histologic data in @entity1 undergoing SG. SETTINGS: University hospital, Rome, Italy. METHODS: From July 2007 to January 2010, 162 @entity1 underwent primary SG. Preoperatively all @entity1 underwent visual analogue scale (VAS) evaluation of @entity354 symptoms, proton pump inhibitors (PPIs) consumption recording, and esophagogastroduodenoscopy (EGD). Stomach resection started 6 cm from pylorus on a 48Fr bougie. Staple line was reinforced by an oversewing suture. A postoperative clinical control with VAS evaluation, PPI consumption, and EGD was proposed to all @entity1 . Three @entity1 were excluded because of the occurrence of major @entity260 . RESULTS: A total of 110 @entity1 accepted to take part in the study (follow-up rate: 69.1%). At a mean 58 months of follow-up, incidence of @entity354 symptoms, VAS mean score, and PPI intake significantly increased compared with preoperative values (68.1% versus 33.6%: P<.0001; 3 versus 1.8: P = .018; 57.2% versus 19.1%: P<.0001) At EGD, an upward migration of the "Z" line and a biliary-like esophageal reflux was found in 73.6% and 74.5% of cases, respectively. A significant increase in the incidence and in the severity of @entity2910 ( @entity2910 ) was evidenced, whereas nondysplastic @entity355 ( @entity355 ) was newly diagnosed in 19 @entity1 (17.2%). No significant correlations were found between @entity354 symptoms and endoscopic findings. CONCLUSION: In the present series the incidence of @entity2910 and of @entity355 in SG @entity1 was considerably higher than that reported in the current literature, and it was not related to @entity354 symptoms. Endoscopic surveillance after SG should be advocated irrespective of the presence of @entity354 symptoms.

title: XXXX and @entity355 after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity355 :: ('MESH:D001471', 'Disease') :: ['BE', "Barrett's esophagus"]

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['erosive esophagitis', 'EE']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity357 :: ('MESH:D006551', 'Disease') :: ['HH', 'hiatal hernia']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux disease', 'GERD']

answer: @entity354 :: (MESH:D005764,Disease) :: ['Gastroesophageal reflux disease']


abstract: BACKGROUND: @entity1211 ( @entity1211 ) is a common complication in @entity5 @entity1 and a significant cause of morbidity and mortality. However, little information is available on oncologists' perceptions of the risk of @entity1211 and its management. The Fundamental Research in Oncology and @entity715 (FRONTLINE) study is the first comprehensive global survey of @entity715 and @entity5 . The study was designed to collect data on the perceived risk and patterns of practice with regard to @entity1211 in @entity5 @entity1 undergoing surgical and medical management of their malignancy and to provide information on international and regional practice patterns, allowing for the design of research studies to answer the concerns of practicing clinicians. METHODS: Literature reviews were performed to provide a current evidence base against which to compare the findings, and a survey was developed under the guidance of an advisory board. A paper-based reply-paid questionnaire was distributed globally between July and November 2001 to clinicians involved in @entity5 care and was made available on a dedicated website. FINDINGS: A total of 3,891 completed responses were available for analysis. Brain and @entity788 were considered to carry a high risk for @entity1211 , and 80% of respondents considered the use of central venous lines to be associated with a high risk of @entity1211 . Marked differences were seen in the use of thromboprophylaxis for surgical and medical @entity5 @entity1 , with over 50% of surgeons reporting that they initiated thromboprophylaxis routinely, while most medical oncologists reported using thromboprophylaxis in less than 5% of medical @entity1 . Low molecular weight heparin (LMWH) was the most popular method of thromboprophylaxis employed in both surgical and medical @entity1 and was more favored by European than U.S. clinicians. Some 20% of respondents reported using @entity117 for prophylaxis, despite there being no reliable evidence for this agent as effective in prevention in this population. For the treatment of @entity1211 , LMWH was again the most common initial treatment, although, for the long-term, oral anticoagulation therapy was widely adopted. Many @entity1 were treated for @entity1211 on an outpatient basis, and secondary prevention of @entity1211 was typically continued for 3 to 6 months after an episode of @entity1150 or for longer in the case of @entity1151 . INTERPRETATION: The results of the FRONTLINE survey demonstrate a need for guidelines to direct clinical practice in line with evidence-based data concerning @entity5 and @entity1211 . Oncologists need to be educated regarding the true risks of @entity1211 associated with certain @entity5 and on strategies for prevention and treatment to reduce the morbidity and mortality associated with @entity1211 in all @entity5 @entity1 . The study has also helped identify areas for future research.

title: Venous thrombosis in XXXX @entity1 : insights from the FRONTLINE survey.

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'Thrombosis']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['Venous thromboembolism', 'VTE']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: 1998, a consensus meeting was held in Miyazaki, Japan, to develop an approach to management of @entity1398 ( @entity1398 ). The K-HOT study group decided to examine whether this proposal was applicable to clinical practice in a multicenter study. @entity1 who developed @entity221 with neutrophil counts <1,000/microL were randomized to receive either a single antibiotic, @entity6944 or one of the @entity2888 , or a combination of @entity6944 and an @entity4028 . @entity1 who became afebrile within the first 3 days were continued on the same treatment. @entity1 who remained febrile were switched to a combination regimen if they were randomized to receive a single agent, and @entity1 on combination medication were changed from @entity6944 to another @entity5898 . A total of 165 @entity1 were entered into the trial. One hundred fifty-three @entity1 were evaluable for response. The average age was 52 years, and 70% of the @entity1 had @entity3052 . Severe @entity1398 , defined as <100/microL at the time of @entity1398 , was seen in 62% of the @entity1 on entry and during the course of treatment 71% of @entity1 experienced neutrophil counts of <100/microL. Microbiologically documented @entity281 was seen in 6.5% for monotherapy, and 10.5% for a combination treatment, and @entity221 of unknown origin occurred in 75.3% and 59.2% of the @entity1 in each regimen, respectively. Excellent to good response was seen in two-thirds of the @entity1 in all treatment groups. Adverse events were minimal, and three early deaths were observed at days 9, 16, and 16 among @entity1 treated with a single antibiotic and three in the combination regimen group at days 14, 15, and 20. These results indicate that @entity6944 or a @entity2893 alone is as effective as a combination of @entity6944 and an @entity4028 for treating @entity1398 .

title: @entity6944 or @entity2893 treatment for @entity1398 as a single agent is as effective as a combination of 4th-generation XXXX + aminoglycosides: comparative study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity6944 :: ('MESH:C043266', 'Chemical') :: ['cefepime']

entities_list: @entity5898 :: ('CHEBI:23066', 'Chemical') :: ['cephalosporin']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute leukemia']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['FN', 'neutropenia', 'febrile neutropenia']

entities_list: @entity2888 :: ('MESH:D015780', 'Chemical') :: ['carbapenems']

entities_list: @entity2893 :: ('CHEBI:46765', 'Chemical') :: ['carbapenem']

entities_list: @entity4028 :: ('CHEBI:47779', 'Chemical') :: ['aminoglycoside']

answer: @entity5898 :: (CHEBI:23066,Chemical) :: ['cephalosporin']